



MK-6892

Catalog No: tcsc1480

Available Sizes	
Size: 5mg	
Size: 10mg	
Size: 50mg	
Size: 100mg	
Specifications	
CAS No: 917910-45-3	
Formula: C ₁₉ H ₂₂ N ₄ O ₅	
Pathway: GPCR/G Protein	
Target: GPR109A	
Purity / Grade: >98%	
Solubility: 10 mM in DMSO	
Observed Molecular Weight: 386.4	

Product Description

MK-6892 is a potent, selective, and full agonist for the high affinity nicotinic acid (NA) receptor **GPR109A**. K_i and GTP γ S **EC**₅₀ of MK-





6892 on the Human GPR109A is 4 nM and 16 nM, respectively.

IC50 & Target: Ki: 4 nM (GPR109A)^[1]

EC50: 16 nM (GPR109A)^[1]

In Vitro: MK-6892 evokes a potent internalization of GPR109A in U2OS β -arrestin2-RrGFP cells.MK-6892 shows an EC₅₀ value of 74 nM on calcium mobilization assay^[2].

In Vivo: MK-6892 is orally administered to WT or nicotinic acid (NA) receptor null mice on the same C57Bl/6 genetic background. After 15 min of 100 mg/kg dosing of MK-6892 to fed WT or NA receptor null mice, the blood levels of MK-6892 at 15 min are 229 μ M (~950-fold greater than the in vitro EC₅₀ determined in mouse NA receptor GTP γ S assay, which is 240 nM) in WT mice and 148 μ M (~620-fold greater than the in vitro EC₅₀) in NA receptor null mice. MK-6892 effectively suppresses plasma FFA in the WT but not in the NA receptor null animals, indicating that the FFA reduction of MK-6892 is NA receptor-dependent. MK-6892 is selected for the studies because of its good PK and activity profiles in these two species (EC₅₀=4.6 μ M in the GTP γ S assay for the rat NA receptor and 1.3 μ M in the GTP γ S assay for the dog NA receptor). Despite the significant weaker activity of MK-6892 in rat and dog with respect to that in human, MK-6892 shows good activity in reducing FFA in rat and dog models^[1].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!